Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly Moy

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
JCO Precision Oncology|January 20, 2022
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerMarko Velimirovic, Dejan Juric, Andrzej Niemierko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional studyInes Vaz-Luis, Rebecca A Ottesen, Melissa E Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineAnn H Partridge, R Bryan Rumble, Lisa A Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysisArielle J Medford, Lauren Oshry, Baris Boyraz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Radiation Oncology (London, England)|August 18, 2020
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancerDavid D Yang, Daniela L Buscariollo, Angel M Cronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
JCO Precision Oncology|January 20, 2022
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerMarko Velimirovic, Dejan Juric, Andrzej Niemierko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional studyInes Vaz-Luis, Rebecca A Ottesen, Melissa E Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineAnn H Partridge, R Bryan Rumble, Lisa A Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysisArielle J Medford, Lauren Oshry, Baris Boyraz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Radiation Oncology (London, England)|August 18, 2020
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancerDavid D Yang, Daniela L Buscariollo, Angel M Cronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
Pageof 17